Inbec常见的不良反应

The ingredients of Suimeike () are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Three drugs are used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir.

Inbec has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. From the comparison with patients who failed the first-line treatment of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), Inbec (Inbec) has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance.

The recommended dosage of Inbec is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Inbec because Inbec is a fixed-dose tablet and the dose cannot be reduced. If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

Clinical safety data for Trimax are limited. The most commonly reported adverse reactions thought to be possibly or probably related to dolutegravir and abacavir/lamivudine (pooled data from 679 antiretroviral-naïve subjects who received this combination in phase IIb to IIIb clinical trials) were nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).

The most common symptoms of a hypersensitivity reaction are: fever (high fever) and rash. Other common reactions include: nausea (feeling like you are throwing up), vomiting, diarrhea, abdominal pain, and tiredness. May also include: joint or muscle pain, neck swelling, shortness of breath, sore throat, cough, occasional headache, eye inflammation (conjunctivitis), mouth sores, low blood pressure, and numbness in the hands and feet. Hypersensitivity reactions can occur at any time during treatment with Trimax®, but are more likely to occur during the first 6 weeks of treatment.